BRAF and metastatic melanoma: The ‘acquired resistance’ occurring in the tumors that were earlier sensitive to BRAF inhibitor treatment has emerged as a major obstacle in the treatment of the patients with late stage metastatic melanoma with BRAFV600E mutation leading to poor prognosis.